Funding Round
Closed Loop Medicine raises $28M Series B for adaptive drug-device combination platform
Syncona Portfolio News4/17/2026·04/17/26🌐 Europe
Summary
London-based Closed Loop Medicine secured $28M Series B led by Syncona, with Adjuvant Capital, M Ventures, and UCB Ventures. The company's platform combines prescription drugs with continuous biosensor monitoring and AI-driven adaptive dosing algorithms. The round will fund Phase 2 trials in hypertension and a new neurological indication targeting epilepsy.
Why it matters
Syncona leading a $28M B-round for closed-loop pharmacology represents a major validation — Syncona focuses exclusively on transformative life science companies with platform potential. The epilepsy neurological indication expansion directly intersects with neurotech and could command device-like margins.
#Closed-Loop#Industry#UK#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in